Johnson & Johnson unit enters $310 million antibiotic deal

Share this article:
Basilea Pharmaceutica of Switzerland has entered into an exclusive worldwide agreement with Johnson & Johnson subsidiary Cilag International for the new antibiotic ceftobiprole.
Cilag will pay a "substantial" upfront payment in the deal worth up to $310 million in scheduled payments.
Ceftobiprole is currently in phase III clinical trials in complicated skin and skin structure infections and hospital-acquired pneumonia trials are in preparation. Both indications have been granted fast track designation by the FDA.
Ortho-McNeil, another Johnson & Johnson company, will market ceftobiprole in the U.S. and its affiliate companies, known as Janssen-Cilag, will market the product outside the U.S.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.